Deerfield Management & Brookside Capital Revealed Significant Stakes in Newly Public Dicerna Pharmaceuticals Inc (DRNA)

In a couple of filings with the Securities and Exchange Commission, Deerfield Management, led by James E. Flynn, and Bain Capital’s Brookside Capital reported holding stakes in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), a company that went public a couple of days ago.  Deerfield disclosed holding a total of  2.42 million common shares of the company, while Brookside's stake amasses 2.34 million shares. Deerfield obtained the securities through the conversion of around 1.43 million Series C Preferred Stock and the acquisition of additional shares at a price of $15 apiece. Dicerna Pharmaceuticals Inc Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), a biopharmaceutical company that focuses on treating rare inherited diseases related to the liver and for cancer, offered 6.0 million shares in its initial public offering at a price of $14.0 per share. The company has partnered with Kyowa Hakko Kirin Co., Ltd. (KHK) for two of its oncology development programs. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) expects to receive clinical, regulatory and commercialization milestone payments for each of its product candidate under research collaboration and license agreement with KHK, of up to $110.0 million. RA Capital Healthcare Fund, an affiliate fund of the Peter Kolchinsky's Ra Capital Management is also a significant shareholder of Dicerna, holding around 1.43 million shares prior to the IPO. Deerfield Management focuses on investment companies that specialize in managing hostile takeovers, funding R&D, corporate transitions and financial advisory services. A couple of months ago, Deerfield Management initiated a passive stake in Horizon Pharma Inc (NASDAQ:HZNP), and revealed owning 4.4 million shares. It also upped its stake in Universal American Corporation (NYSE:UAM) to 4.4 million shares, from 2.9 million shares, and boosted its position in Capital Senior Living Corporation (NYSE:CSU) to 1.8 million shares from 1.1 million shares held earlier. Brookside Capital is a long/short public equities fund, using fundamental analysis as well as industry and competitive, it invests across all economic sectors. Brookside Capital held 2.28 million shares of Monsanto Company (NYSE:MON) at the end of the third quarter of 2013. The fund was also bullish on Youku Tudou Inc (ADR) (NYSE:YOKU), and held 8.15 million shares at the end of the third quarter. Disclosure: none Recommended reading: Michael Messner’s Seminole Capital Top Picks From the Latest 13F Hedge Fund Highlights: Jeffrey Altman, Seth Klarman & Ken Griffin Sanford J. Colen Sends Letter To Board of MicroStrategy (MSTR); Wants Investor Communication Program
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 30 percentage points in 13 months Learn how!

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!